A national study of self-reported COVID symptoms during the first viral wave in Canada

Xuyang Tang (1), Hellen Gelband (1), Teresa Lam (2), Nico Nagelkerke (1), Angus Reid (2), Prabhat Jha (1)
for the Action to beat Coronavirus (Ab-C) Study Investigators

Affiliations:

- (1) Centre for Global Health Research (CGHR), Unity Health Toronto and University of Toronto,
Toronto, Ontario, Canada
- (2) Angus Reid Forum, Toronto, Ontario, Canada

Corresponding author and address:

Prabhat Jha, MD, DPhil,
30 Bond Street
Toronto, ON, M5B 1W8, Canada
Email: prabhat.jha@utoronto.ca

Abstract

Importance: Accurate understanding of COVID pandemic during the first viral wave in Canada could help prepare for future epidemic waves.

Objective: To track the early course of the pandemic by examining self-reported COVID symptoms over time before testing became widely available.

Design: Adults from the nationally representative Angus Reid Forum were randomly invited to complete an online survey in May/June 2020. The study is a part of the Action to Beat Coronavirus antibody testing study.

Setting: A 20-item internet survey.

Participants: 14,408 adults age 18 years of age.

Exposures: The months that respondents and any household members first experienced various respiratory, neurological, sleep, skin or gastric symptoms.

Main Outcomes and Measure: “COVID symptom-positive,” defined as fever (or fever with hallucinations) plus at least one of difficulty breathing, a dry severe cough, loss of smell or “COVID toe.”

Results: In total, 14,408 panel members (48% male and 52% female) completed the survey. Despite overrepresentation of higher levels of education, the prevalence of obesity, smoking, diabetes and hypertension were similar to national census and health surveys. A total of 811 (5.6%) were COVID symptom-positive; highest rates were at ages 18-44 years (8.3% among), declining at older ages. Females had higher odds of reporting COVID symptoms (OR = 1.32, 95%CI 1.11 – 1.56) as did visible minorities (OR = 1.74, 1.29 – 2.35). COVID symptom positivity for respondents and their household members peaked in March (OR = 1.93, 95% CI = 1.59 – 2.34 compared to earlier months).

Conclusions and Relevance: This study enhances our current understanding of the progression of the COVID epidemic in Canada, with few laboratory-confirmed cases in January and February, peaking in April. The results suggest substantial viral transmission in March, before widespread testing began, and a gradual decline in cases since May.

Main Text

Introduction

The SARS-CoV-2/COVID pandemic has caused serious morbidity and claimed many lives, notably among the elderly, those suffering from chronic illnesses (e.g., diabetes, hypertension, vascular diseases, obesity), or a history of smoking, especially in ethnic minorities.¹ Canada reported, as of September 1, about 130,000 cases and over 9,000 deaths, the latter mostly in nursing home residents.² Prior to mid-July, testing was reserved for contacts and those with symptoms or high-risk occupations. Thus, the overall proportion of Canadians testing positive (100,000/32 million adults) was well below 0.5%, likely representing only some fraction of all infections during the first viral wave.

Accurately tracking the development of the pandemic helps to understand transmission, and thereby prepare for future epidemic waves. We sought to track the course of the pandemic in Canada before diagnostic testing was widely available by tracking self-reported symptoms of COVID during the early months of viral spread.

The Ab-C study³ is a collaboration of the University of Toronto, Unity Health Toronto, and the Angus Reid Institute,⁴ a Canadian public opinion polling organization. This paper reports on results of the first component of the Ab-C study: a survey of COVID symptoms during March-June among a well-characterized representative sample of Canadian adults. Results of the second component—antibody analyses of self-administered dried blood spots from the survey population—will be reported in the coming months.

Methods

Study design and survey description

Participants were members of an established panel of Canadians age 18 and older, called the Angus Reid Forum. Forum members were stratified by age, sex, education and province or territories of residence, and then randomly invited on a rolling basis to participate in the online survey portion of the Ab-C study, during which the respondents could opt in for later antibody testing. Members age 60-85 were oversampled because of their elevated risk of serious COVID morbidity and mortality. However, the sampling frame included very few elderly nursing home residents. The Unity Health Toronto Research Ethics Board approved this study (REB# 20-107).

The online survey assessed concerns about COVID of respondents and their household members, whether and when they had or still have specific symptoms typically associated with COVID, testing for COVID and their intention to seek testing, work in high-risk professions for COVID, visits to medical facilities since the beginning of February 2020, and demographic and health status.

Measures and variables

Symptoms

Several retrospective studies that enrolled over a hundred COVID patients in hospitals in mainland China have identified fever⁵⁻¹¹ and cough (dry or unspecified)^{5,7-11} as commonly associated with the infection. Other symptoms experienced by patients in China include a lack of appetite,⁶ general weakness,⁶ malaise,¹⁰ myalgia or fatigue,^{7,10,11} diarrhea,⁶ excess sputum production,⁷ shortness of breath^{8,10} and sore

throat.¹¹ A study that examined 1,420 COVID patients from 18 hospitals in Europe found that headache and loss of smell were present in over 70% of the cases.¹² A cutaneous manifestation (also known as “COVID toe”), appearing similar to skin rash, was common among 375 COVID patients in Spain.¹³ The online Ab-C survey questions about COVID symptoms drew on these findings.

We asked respondents if they had experienced any of the following symptoms that were not related to a condition or illness that they dealt with chronically: difficulty breathing, fever, dry mild cough, severe dry cough (“keeps you from sleeping”), sore throat, frequent sneezing, loss of sense of smell or taste, fever with hallucinations, unusual or disturbed sleep, loss of appetite, dizziness, and red, purple, pink toes with swelling. For each symptom, the possible responses were “Yes, had this but it went away”, “Yes, I still have this”, and “No, have not had this.” We also asked respondents for the month they first had these symptoms, and if they were still having any of them. We asked the respondents the same questions about their household members’ experience with the same symptoms.

We created separate COVID symptom variables for respondents and for household members. We defined COVID symptom-positive as a combination of fever (or fever with hallucinations) with difficulty breathing, a dry cough, loss of smell or “COVID toe.” We created a categorical variable to indicate if no one in the household, only the respondent, only other household member(s), or both the respondent and household member(s) were COVID symptom-positive.

Demographics and health

Respondents reported their birth year and month, sex (male/female/prefer to self-describe), highest level of education (some elementary or high school/high school graduate/some college or trade school/graduated from college or trade school/some university/university undergraduate degree/university graduate degree), height, weight, current smoking status (never smoked/smoked daily or occasionally/used to smoke but quit/don’t know/prefer not to answer), diagnosis of diabetes (yes/no/don’t know/prefer not to answer), and diagnosis of high blood pressure (yes/no/don’t know/prefer not to answer). We calculated respondents’ body mass index (BMI) from self-reported height and weight, and categorized BMI as normal or underweight ($BMI < 25 \text{ kg/m}^2$), overweight ($25 \text{ kg/m}^2 \leq BMI < 30 \text{ kg/m}^2$), and obese ($BMI \geq 30 \text{ kg/m}^2$).¹⁴ The online poll has existing information on the respondents’ age in years, ethnicity (including whether they self-identify as a visible minority) and region of residence based on their membership information.

Statistical analysis

We present the proportion of respondents who were COVID symptom-positive by month of onset and age group, and the distribution of COVID symptom-positivity in households by month of onset and age group. We used simple logits to calculate the likelihood of COVID symptom-positivity by month in the overall sample adjusting for known demographic and health risk factors. We excluded responses from 638 respondents with questionable self-reported height (< 100 or > 221 centimeters) and 1,080 respondents with questionable self-reported weight (< 30 or > 200 kilograms) from the logit but not for other analyses that do not require weight and height information. We used Stata SE 13¹⁵ to conduct our analyses.

Results

A total of 14,408 of 31,839 invited Forum members completed the online survey. The demographics and health characteristics of those completing the online poll are summarized in Table 1, alongside the proportion of population with those characteristics in the Canadian population overall, from various sources. The distribution of demographic characteristics of the respondents in the Ab-C study are similar to those from the 2016 Census Canada,^{16–19} with the exception of an overrepresentation of adults with some university education (49% in our sample versus 32% in Canada). Despite this, the Ab-C study participants were quite similar to the national prevalences of obesity, current smoking, diabetes and hypertension, as reported by Public Health Agency of Canada,²⁰ Health Reports²¹ and Health Canada.^{22,23}

Time trends

In the sample, 7,309 respondents experienced at least one of the survey symptoms, and 811 (6% of the entire cohort) met the study definition of COVID symptom-positivity (Table 2). Table 2 presents respondents' prevalences and odds ratios (OR) of COVID symptoms. After adjusting for age, sex, ethnicity, education, province of residence, BMI, smoking status, and history of diabetes and hypertension, the likelihood of COVID symptom-positivity were highest among younger adults aged 18–44 (8.3%), and fell in older age groups, to 2.9% at 65–74 years and 3.4% at 75 years and older (OR of about 0.48 in the last two age groups). Females had higher odds of reporting COVID symptoms (OR = 1.32, 95%CI 1.11 – 1.56) as did visible minorities (OR = 1.74, 1.29 – 2.35).

Figure 1 shows the proportion of respondents COVID symptom-positive in each month among those reporting any symptom in all ages and by age group. March had the highest proportion of COVID symptom-positive respondents (20.6%) of those reporting any symptom in all age groups. In April, a higher proportion of respondents age 18–44 were COVID symptom-positive (12.2%) than respondents in older age groups (9.3% in age 45–64, 4.2% in age 65–74 and 2.6% in age 75 years and older). However, the 75+ group saw an increase (8.6%) of COVID symptom-positivity in May or later. The corresponding OR compared to February or earlier were in March (OR = 1.93, 1.59 – 2.34), falling in April (OR = 0.78, 0.61 – 1.00) and May or later (OR = 0.32, 0.08 – 0.23). (Table 2) The counts of COVID symptom positivity among those who experienced any symptom by month and age group are presented in Appendices A and B.

In the sample with at least two household members, the proportion of those reporting COVID symptoms was the same (5.6%). In these households, 4,175 reported any symptom in someone else aside from the respondent of which 651 (16%) reported COVID symptoms. Figure 2 presents the distribution of COVID symptom positivity in households with at least two members, by month and respondents' age group. Of the 651 households, 351 reported COVID symptom only in household members but not the respondent, while 300 reported COVID symptom in both household members and the respondent. March was also the peak of COVID symptom positivity for respondents and/or their household members for all age groups, followed by declines of COVID symptom positivity in April and later months. In March, respondents aged 75 and above were more likely than younger respondents to be the only one in a multi-person household with symptoms (21% in age 75+ vs. 11% in age 18–44, 8% in age 45–64, 10% in age 65–74).

Discussion

In our sample of 14,408 Canadian adults, 5.6% of met the study definition of COVID symptom-positivity during the March-June period of Canada's first viral wave. The highest prevalence was among younger adults, women and visible minorities. COVID symptoms were highest in March 2020, at 2.6%. Results were similar among household respondents, as has been noted for an earlier smaller national poll²⁴. Among our respondents, most of the demographic and health risk factors for COVID mortality established in earlier studies (e.g., smoking status, obesity, history of diabetes or high blood pressure)^{1,25,28} were not associated with elevated odds of COVID symptom-positivity, suggesting that such factors may not affect the likelihood of developing symptoms but rather increase the probability of hospitalization and dying from COVID once infected or developing symptoms.

The March peak of symptoms is roughly consistent with the current understanding of the pandemic in Canada. Until about mid-July, only symptomatic patients, close contacts, those with a travel history to high-risk regions or high-risk occupations were permitted SARS-COV-2 testing. The official peak, based on testing, was April, but it is likely based on our results that significant transmission was taking place earlier. This is also consistent with the May peak in COVID deaths²⁶ (Figure 3). Most of the COVID deaths occurred in nursing home populations, but community deaths followed a similar pattern.²

A strength of this study is using a sample with demographics and health characteristics similar to that of all Canadian adults from a well-characterized polling panel. The study has certain limitations. Symptom positivity data are available only monthly rather than weekly, which would have given us a finer tuned look at the shape of the symptom curve. However, monthly data are less likely to be misreported retrospectively. Also, there is the potential for reporting biases. Overreporting, i.e., low specificity of symptoms for COVID, could result from time-varying knowledge and awareness of COVID effects. We examined household distribution of less common symptoms (e.g., loss of appetite, dizziness, disturbed sleep) to see whether participants and their household members simply noticed symptoms because of the pandemic or whether they truly experienced symptoms, using graphs similar to Figure 2. The shape of the graphs is generally consistent with Figure 2 which suggests that respondents may not have enhanced reporting of symptoms as they become more aware of COVID (data not shown). Naturally, self-reported symptoms may represent not just COVID but other conditions, including seasonal influenza. Symptoms also have low sensitivity for COVID as notable proportion of (infectious) COVID cases are asymptomatic.²⁷

The next phase of the study will as combine survey responses with antibody testing results as well as examining the discordance of symptoms and antibodies in multi-person households. The antibody collection started in mid-June, which should allow for testing of at least IgG antibodies which have been shown to be stable for a few months after infection²⁸. As such, it will provide a unique insight on the first viral wave in Canada.

This study enhances our current understanding of the progression of the COVID epidemic in Canada, with symptoms peaking in March. There were few laboratory-confirmed cases in January and February, with these peaking in April. The results suggest substantial viral transmission in March, before widespread testing began, and a gradual decline in cases since May.²⁹

References

1. National Center for Immunization and Respiratory Diseases (NCIRD). Assessing Risk Factors for Severe COVID-19 Illness. Division of Viral Diseases. Center for Disease Control and Prevention. <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/assessing-risk-factors.html>. Published 2020. Accessed August 25, 2020.
2. Holroyd-Leduc JM, Laupacis A. Continuing care and COVID-19: a Canadian tragedy that must not be allowed to happen again. *Can Med Assoc J*. 2020;192(23):E632-E633. doi:10.1503/cmaj.201017
3. Jha P, Birnboim HC, Bogoch I, et al. Action to beat coronavirus. <https://www.abcstudy.ca/>. Published 2020. Accessed August 25, 2020.
4. Angus Reid Forum. Angus Reid Forum Inc. <https://www.angusreidforum.com/en-ca/About>. Published 2019. Accessed August 25, 2020.
5. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis*. 2020;20(4):425-434. doi:10.1016/S1473-3099(20)30086-4
6. Pan L, Mu M, Yang P, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: A descriptive, cross-sectional, multicenter study. *Am J Gastroenterol*. 2020;115(5):766-773. doi:10.14309/ajg.0000000000000620
7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
8. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7
9. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032
10. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020;8(5):475-481. doi:10.1016/S2213-2600(20)30079-5
11. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (covid-19) pneumonia: A multicenter study. *Am J Roentgenol*. 2020;214(5):1072-1077. doi:10.2214/AJR.20.22976
12. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and Epidemiological Characteristics of 1,420 European Patients with mild-to-moderate Coronavirus Disease 2019. *J Intern Med*. 2020:1-10. doi:10.1111/joim.13089
13. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. *Br J Dermatol*. 2020;183(1):71-77. doi:10.1111/bjd.19163
14. About Adult BMI. Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion. https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html. Published 2020. Accessed August 25, 2020.
15. StataCorp. Stata. 2013. <https://www.stata.com/>.
16. Catalogue no.: 98-402-X2016010. *Education Highlight Tables, 2016 Census*. Ottawa, ON; 2017. <https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/hltfst/edu-sco/index-eng.cfm>. Accessed August 25, 2020.
17. Catalogue no.: 98-402-X2016009. *Aboriginal Peoples Highlight Tables, 2016 Census*. Ottawa, ON; 2017. <https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/hltfst/abo-aut/index-eng.cfm>. Accessed August 25, 2020.

18. Catalogue no.: 98-316-X2016001. *Census Profile, 2016 Census*. Ottawa, ON; 2020. <https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/index.cfm?Lang=E>. Accessed August 25, 2020.
19. Table: 17-10-0134-01. Estimates of population (2016 Census and administrative data), by age group and sex for July 1st, Canada, provinces, territories, health regions (2018 boundaries) and peer groups. *Data*. 2020. <https://doi.org/10.25318/1710013401-eng>. Accessed August 25, 2020.
20. Chronic Disease Surveillance and Monitoring Division. *Diabetes in Canada: Facts and Figures from a Public Health Perspective – Burden*. Ottawa, ON; 2011. <https://www.canada.ca/en/public-health/services/chronic-diseases/reports-publications/diabetes/diabetes-canada-facts-figures-a-public-health-perspective/chapter-1.html#DIA>.
21. DeGuire J, Clarke J, Rouleau K, Roy J, Bushnik T. Blood pressure and hypertension. *Heal Reports*. 2019;February. <https://www.doi.org/10.25318/82-003-x201900200002>.
22. Health Canada. *Canadian Tobacco, Alcohol and Drugs Survey (CTADS): Summary of Results for 2017*. Ottawa, ON; 2017. <https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-survey/2017-summary.html>.
23. Health Fact Sheets. *Overweight and Obese Adults, 2018*. Ottawa, ON; 2019. <https://www150.statcan.gc.ca/n1/en/pub/82-625-x/2019001/article/00005-eng.pdf?st=WObpH-hz>.
24. Chan AT, Brownstein JS. Putting the Public Back in Public Health — Surveying Symptoms of Covid-19. *N Engl J Med*. 2020;383(7):e45. doi:10.1056/NEJMp2016259
25. Ward H, Atchison CJ, Whitaker M, et al. Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults. *medRxiv*. 2020. doi:10.1101/2020.08.12.20173690
26. Brown P, Jha P, CGHR COVID Mortality Consortium. Mortality from COVID-19 in 12 countries and 6 states of the United States. *medRxiv*. 2020. doi:10.1101/2020.04.17.20069161
27. Gandhi M, Yokoe DS, Havlir D V. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. *N Engl J Med*. 2020;382(22):2158-2160. doi:10.1056/NEJMe2009758
28. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med*. September 2020;NEJMoa2026116. doi:10.1056/NEJMoa2026116
29. Coronavirus disease (COVID-19): Outbreak update. Government of Canada. <https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection.html>. Published 2020. Accessed August 27, 2020.

Tables

Table 1. Demographic, health characteristics and experience of any symptom in the sample with comparison to 2016 Census Canada, Public Health Agency of Canada, Stats Can and Health Canada

Characteristics	Canada	Ab-C
	%	No. (%)
Age categories ^a		
18 to 44	36%	5,006 (35%)
45 to 64	27%	5,415 (38%)
65 to 74	10%	3,228 (22%)
75 and older	7%	759 (5%)
Sex ^a		
Male	49%	6,911 (48%)
Female	51%	7,424 (52%)
Prefer to self-describe		73 (1%)
Education ^a		
High school graduate or under	35%	2,070 (14%)
Some college or college graduate	33%	5,316 (37%)
Some university or higher	32%	7,022 (49%)
Household size ^a		
Just one – I live alone	28%	2,638 (18%)
Two people	34%	6,417 (45%)
Three people	15%	2,363 (16%)
Four people	14%	1,923 (13%)
Five or more people in my household	8%	1,067 (7%)
Respondent ethnicity ^a		
Indigenous	5%	696 (5%)
English and other European	73%	12,191 (85%)
Others	22%	1,140 (8%)
Rather not say		381 (3%)
Visible Minority ^a		
No	78%	12,797 (89%)
Yes	22%	1,611 (11%)
Province ^a		
Ontario	38%	5,601 (39%)
British Columbia	13%	2,072 (14%)
Quebec	23%	2,887 (20%)
Prairie provinces	18%	2,679 (19%)
Atlantic provinces	7%	1,169 (8%)
Weight status (calculated from Body Mass Index) ^d		
Under or Normal Weight (BMI < 25 kg/m ²)	37%	4,130 (33%)
Overweight (25 kg/m ² ≤ BMI < 30 kg/m ²)	37%	4,690 (37%)
Obese (BMI ≥ 30 kg/m ²)	27%	3,870 (31%)

Currently smoking		
No		12,465 (86%)
Yes (Daily or occasional) ^d	15%	1,943 (14%)
Ever diagnosed as diabetic		
No		12,736 (88%)
Yes ^b	9%	1,536 (11%)
Do not know or Preferred not to answer		136 (1%)
Ever diagnosed as hypertensive		
No		9,951 (69%)
Yes ^c	23%	4,241 (29%)
Do not know or Preferred not to answer		216 (2%)
Experience with <u>any</u> symptom		
Had symptom before March		2,198 (15%)
Had symptom in March		1,789 (12%)
Had symptom in April		1,264 (9%)
Had symptom in May or later		962 (7%)
Had symptom but cannot recall the month		1,096 (8%)
Did not have symptom		7,099 (49%)

Sources: a. 2016 Census Canada¹⁶⁻¹⁹; b. Public Health Agency of Canada²⁰; c. Health Reports²¹; d. Health Canada^{22,23}

Table 2. Respondents' odds ratio of COVID symptom positivity

	COVID symptoms		OR ^c	(95% CI ^d)
	positive/negative or asymptomatic ^a	% positive		
Age categories				
18 to 44	413/4593	8.3%	ref	
45 to 64	278/5137	5.1%	0.73***	(0.60 - 0.89)
65 to 74	94/3134	2.9%	0.47***	(0.35 - 0.63)
75 and older	26/733	3.4%	0.48***	(0.29 - 0.81)
Sex				
Male	319/6592	4.6%	ref	
Female	486/6938	6.5%	1.30***	(1.10 - 1.54)
Preferred not to answer	6/67	8.2%	1.53	(0.32 - 7.22)
Education				
HS graduate or under	85/1985	4.1%	ref	
some college or college graduate	283/5033	5.3%	1.17	(0.87 - 1.56)
some university or higher	443/6579	6.3%	1.16	(0.87 - 1.54)
Household size				
1 person	156/2482	5.9%	ref	
2 people	331/6086	5.2%	0.87	(0.69 - 1.10)
3 people	118/2245	5%	0.62***	(0.46 - 0.83)
4 people	131/1792	6.8%	0.77*	(0.58 - 1.03)
5 people or more	75/992	7%	0.83	(0.59 - 1.16)
Visible minority				
No	674/12123	5.3%	ref	
Yes	137/1474	8.5%	1.73***	(1.28 - 2.34)
Ethnicity				
English and other European	646/11545	5.3%	ref	
Indigenous	57/639	8.2%	1.09	(0.78 - 1.54)
Other	87/1053	7.6%	0.69**	(0.48 - 1.00)
Rather not say	21/360	5.5%	1.14	(0.66 - 1.96)

Province				
Ontario	386/5215	6.9%	ref	
British Columbia	106/1966	5.1%	0.83	(0.65 - 1.07)
Quebec	140/2747	4.8%	0.79**	(0.63 - 1.00)
Prairie provinces	131/2548	4.9%	0.80*	(0.63 - 1.01)
Atlantic provinces	48/1121	4.1%	0.67**	(0.48 - 0.95)
Weight status				
Under or Normal Weight (BMI < 25 kg/m ²)	255/3875	6.2%	ref	
Overweight (25 kg/m ² ≤ BMI < 30 kg/m ²)	248/4442	5.3%	1.01	(0.83 - 1.23)
Obese (BMI ≥ 30 kg/m ²)	191/3679	4.9%	0.97	(0.78 - 1.20)
Smoking Status				
No	694/11771	5.6%	ref	
Yes (Daily or Occasional)	117/1826	6%	1.07	(0.85 - 1.36)
Ever diagnosed as diabetic				
No	713/12023	5.6%	ref	
Yes	77/1459	5%	1.33*	(0.98 - 1.80)
Do not know or Preferred not to answer	21/115	15.4%	1.64	(0.62 - 4.35)
Ever diagnosed as hypertensive				
No	593/9358	6%	ref	
Yes	196/4045	4.6%	1.00	(0.80 - 1.25)
Do not know or Preferred not to answer	22/194	10.2%	1.42	(0.68 - 2.97)
Symptom Onset				
	Positive/negative excluding asymptomatic ^b	% positive	OR	(95% CI)
Before March	251/1947	11.4%	ref	
March	368/1421	20.6%	1.93***	(1.59 - 2.34)
April	122/1142	9.7%	0.78**	(0.61 - 1.00)
May or later	44/918	4.6%	0.32***	(0.22 - 0.46)
Cannot remember	26/1070	2.4%	0.13***	(0.08 - 0.23)
Constant			0.16***	(0.11 - 0.24)
Observations	6,476			

Notes:

*** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$

^a Denominator includes asymptomatic respondents and those with some but not COVID symptoms.

^b Denominator only includes respondents with some but not COVID symptoms.

^c OR and 95% CI excludes the 638 observations with questionable self-reported height and weight.

Figures

Figure 1. COVID symptom positivity by month of onset and age group

Figure 2. Household distribution of COVID symptom by time and respondent age group

Figure 3. COVID symptom positivity among Ab-C respondents compared to COVID cases and deaths in Canada

Appendices

Appendix A. Counts of COVID symptom in respondents and household members by age groups and month of symptoms' onset.

Part A. Number of respondents with COVID symptom among those reported any symptom by the month of symptoms' onset and age group

Age group	COVID symptom	Before March	March	April	May or later	Cannot recall	Total
All ages	No	1,947	1,421	1,142	918	1,070	6,498
	Yes	251	368	122	44	26	811
Age 18 to 44	No	653	651	503	381	372	2,560
	Yes	96	210	70	21	16	413
Age 45 to 64	No	732	525	418	305	391	2,371
	Yes	105	110	43	15	5	278
Age 65 to 74	No	443	211	183	200	241	1,278
	Yes	42	36	8	5	3	94
Age 75 and older	No	119	34	38	32	66	289
	Yes	8	12	1	3	2	26

Part B. Number of household members (in 2+ member households) with COVID symptom among those reported any symptom by the month of symptoms' onset and age group

Age group	COVID symptom	Before March	March	April	May or later	Cannot recall	Total
All ages	No	789	897	687	561	590	3,524
	Yes	176	314	98	46	17	651
Age 18 to 44	No	280	453	347	276	236	1,592
	Yes	89	195	50	29	12	375
Age 45 to 64	No	297	336	237	190	202	1,262
	Yes	63	91	34	11	4	203
Age 65 to 74	No	168	95	91	83	119	556
	Yes	21	26	12	4	1	64
Age 75 and older	No	44	13	12	12	33	114
	Yes	3	2	2	2	0	9

Appendix B. Ab-C Study Investigators

St. Michael's Hospital (Unity Health Toronto)

Centre for Global Health Research P Jha (Principal Investigator), P Brown (scientist), H Gelband (senior fellow), N Nagelkerke (senior fellow), E Young (coordinator), A Sharma (coordinator), P Rodriguez (coordinator), C Schultz (coordinator), C Birnboim (senior consultant), L Newcombe; *Applied Health Research Centre*, P Juni (scientist); *Keenan Research Centre for Biomedical Science* H Ni (platform director, Scientist); *Immunology Laboratory* M Pasic (Division Head); *Li Ka Shing Knowledge Institute* G Booth (scientist); Arthur Slutsky, Scientist (scientist, Chair, Scientific Advisory Board)

University Health Network

I Bogoch (scientist)

Sinai Health

AC Gingras (scientist), K Colwill (coordinator)

Children's Hospital of Eastern Ontario and University of Ottawa

P Chakraborty (scientist), MA Langlois (scientist)

Angus Reid Forum

A Reid, E Morawski, D Eliopoulos, A Hollander